Physicochemical characterization and phase I study of CMAB008, an infliximab biosimilar produced by a different expression system
Sign Up to like & getrecommendations! Published in 2019 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s170913
Abstract: Background Infliximab (Remicade), a chimeric monoclonal antibody against human TNFα, will inevitably face competition from biosimilar products, because of its effectiveness in autoimmune diseases and rapidly increasing market demand. According to guidelines for biosimilar development,… read more here.
Keywords: expression; expression system; cmab008 infliximab; infliximab biosimilar ... See more keywords